underscored material = new
[bracketed material] = delete
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
HOUSE MEMORIAL 58
57TH LEGISLATURE - STATE OF NEW MEXICO - FIRST SESSION, 2025
INTRODUCED BY
Dayan Hochman-Vigil
A MEMORIAL
REQUESTING THE DEPARTMENT OF HEALTH TO STUDY PSILOCYBIN-BASED
MEDICATION TREATMENT.
WHEREAS, psilocybin, a naturally occurring psychedelic
compound found in certain mushrooms, has gained recognition for
its potential therapeutic applications, including treatment for
mental health conditions such as depression, anxiety and
posttraumatic stress disorder; and
WHEREAS, the use of psilocybin-based treatments has become
a topic of increasing interest in the medical and scientific
communities, with several jurisdictions across the United
States and globally exploring regulatory frameworks for the use
of psilocybin-based treatments in clinical settings; and
WHEREAS, New Mexico has recognized the importance of
advancing evidence-based health care solutions and ensuring the
.231353.2 underscored material = new
[bracketed material] = delete
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
safety, efficacy and accessibility of new treatment modalities
for its residents; and
WHEREAS, the department of health plays a central role in
regulating health care practices and safeguarding public health
within the state; and
WHEREAS, New Mexico would benefit from standardized
guidelines that ensure appropriate training for medical
professionals and robust testing protocols for psilocybin-based
treatments;
NOW, THEREFORE, BE IT RESOLVED BY THE HOUSE OF
REPRESENTATIVES OF THE STATE OF NEW MEXICO that the department
of health be requested to study the following:
A. the standardization of training requirements and
modalities for the use of psilocybin-based medication treatment
by examining the current landscape of psilocybin-based
medication treatments;
B. the establishment of clear testing protocols to
ensure the consistency, accuracy and safety of psilocybin
products;
C. the methods for determining psilocybin content,
variability in potency and quality control measures that
protect both patients and providers;
D. the considerations of both initial and ongoing
training requirements, ensuring that the training modalities
support safe, effective and ethical use of psilocybin as a
.231353.2
- 2 - underscored material = new
[bracketed material] = delete
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
therapeutic treatment;
E. the review of existing legal and regulatory
barriers to psilocybin-based medication treatment, including
state and federal restrictions, and recommendations for policy
adjustments that may facilitate safe and controlled access;
F. the examination of potential frameworks for
licensing, administration and oversight, including whether
psilocybin-based treatment should be limited to medical
professionals, offered in supervised clinical settings or made
available through licensed facilitators;
G. the evaluation of public health and safety
concerns, including considerations for proper screening of
patients, contraindications and integration with existing
mental health care services;
H. the assessment of economic and social equity
impacts, including strategies to ensure affordable and
equitable access to psilocybin-based treatments for underserved
populations, as well as opportunities for community
participation in the development of a regulatory framework;
I. the engagement of medical and scientific
experts, including representatives from universities, research
institutions and clinical trial programs, to provide guidance
on evidence-based best practices and safety standards;
J. the solicitation of input from stakeholders,
including health care professionals, indigenous and traditional
.231353.2
- 3 - underscored material = new
[bracketed material] = delete
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
medicine practitioners, mental health advocacy organizations
and members of the public, to inform policy recommendations;
K. the identification of potential funding sources
for future research and implementation efforts, including
federal grants, private research partnerships and state
appropriations; and
L. the establishment of a time line for
implementing any recommended regulatory or legislative changes
following the completion of the study, ensuring that findings
are used to inform future policymaking efforts; and
BE IT FURTHER RESOLVED that the department of health be
requested to submit a comprehensive report detailing the
department's findings, recommended policy changes and a
proposed framework for psilocybin-based medication treatment,
including potential pilot programs, licensing structures and
public health safeguards; and
BE IT FURTHER RESOLVED that a copy of this memorial be
transmitted to the secretary of health.
- 4 -
.231353.2